Sign In

Login

Password

Forgot Password ? Sign Up

Razoxano (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Razoxano" in Italian language version.

refsWebsite
Global rank Italian rank
25nih.gov
4th place
9th place
3oadoi.org
799th place
22nd place
3doi.org
2nd place
7th place

doi.org

dx.doi.org

nih.gov

ncbi.nlm.nih.gov

  • K. Hellmann, EO. Field, Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy., in J Natl Cancer Inst, vol. 44, n. 3, Mar 1970, pp. 539-43, PMID 11515423.
  • RL. Jones, Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity., in Expert Rev Cardiovasc Ther, vol. 6, n. 10, Nov 2008, pp. 1311-7, DOI:10.1586/14779072.6.10.1311, PMID 19018683.
  • SK. Bjelogrlic, J. Radic; S. Radulovic; M. Jokanovic; V. Jovic, Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo., in Exp Biol Med (Maywood), vol. 232, n. 11, Dec 2007, pp. 1414-24, DOI:10.3181/0705-RM-138, PMID 18040065.
  • P. Xiang, HY. Deng; K. Li; GY. Huang; Y. Chen; L. Tu; PC. Ng; NH. Pong; H. Zhao; L. Zhang; RY. Sung, Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model., in Cancer Chemother Pharmacol, vol. 63, n. 2, Jan 2009, pp. 343-9, DOI:10.1007/s00280-008-0744-4, PMID 18379782.
  • PJ. Creaven, LM. Allen; DA. Alford, The bioavailability in man of ICRF-159 a new oral antineoplastic agent., in J Pharm Pharmacol, vol. 27, n. 12, Dec 1975, pp. 914-8, PMID 2662.
  • K. Hellmann, MB. Grimshaw; GE. Hutchinson, Combination of radiation and razoxane (ICRF 159) in vivo., in Int J Radiat Oncol Biol Phys, vol. 4, n. 1-2, pp. 109-13, PMID 632139.
  • WU. Rhomberg, Radiotherapy combined with ICRF 159 (NSC 129943)., in Int J Radiat Oncol Biol Phys, vol. 4, n. 1-2, pp. 121-6, PMID 204615.
  • K. Hellmann, M. Goold; N. Higgins; RH. Phillips, Responses of liver metastases to radiotherapy and razoxane., in J R Soc Med, vol. 85, n. 3, Mar 1992, pp. 136-8, PMID 1556714.
  • RD. Ryall, Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas., in Int J Radiat Oncol Biol Phys, vol. 4, n. 1-2, pp. 133-4, PMID 632140.
  • W. Rhomberg, E. Mesche; D. Gefeller; E. Hassenstein, [Clinical experiences with radiotherapy and ICRF 159 in sarcomas]., in Strahlentherapie Sonderb, vol. 75, 1978, pp. 110-4, PMID 400195.
  • CL. Olweny, JP. Masaba; W. Sikyewunda; T. Toya, Treatment of Kaposi's sarcoma with ICRF-159 (NSC-129943)., in Cancer Treat Rep, vol. 60, n. 1, Jan 1976, pp. 111-3, PMID 1000514.
  • A. Chachoua, M. Green; J. Wernz; F. Muggia, Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's sarcoma (AIDS-KS)., in Invest New Drugs, vol. 7, n. 4, Nov 1989, pp. 327-31, PMID 2513285.
  • CL. Olweny, W. Sikyewunda; D. Otim, Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma., in Oncology, vol. 37, n. 3, 1980, pp. 174-6, PMID 7360489.
  • P. Krepler, J. Pawlowsky, Clinical trials with bis-dioxopiperazine propane (ICRF 159; NSC 129, 943) in acute leukaemias., in Osterr Z Onkol, vol. 2, n. 4, 1975, pp. 112-4, PMID 772517.
  • Razoxane in treatment of acute myeloid leukaemia., in Br Med J, vol. 2, n. 6145, Oct 1978, p. 1161, PMID 280402.
  • S. Krasnow, PA. Bunn; DC. Ihde; MJ. Matthews; MH. Cohen; J. Eddy; JD. Minna, ICRF-159 in advanced gastric cancer. Absence of activity., in Am J Clin Oncol, vol. 5, n. 6, Dec 1982, pp. 635-9, PMID 7165006.
  • HD. Homesley, JA. Blessing; J. Conroy; K. Hatch; PJ. DiSaia; LB. Twiggs, ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study., in Am J Clin Oncol, vol. 9, n. 1, Feb 1986, pp. 15-7, PMID 3953488.
  • HD. Homesley, JA. Blessing; M. Berman, ICRF-159 (razoxane) in patients with advanced nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study., in Am J Clin Oncol, vol. 9, n. 4, Aug 1986, pp. 325-6, PMID 3751970.
  • GW. Hill, M. Roach, Razoxane in the treatment of psoriasis., in Br J Dermatol, vol. 103, n. 5, Nov 1980, pp. 583-5, PMID 7437323.
  • DJ. Atherton, RS. Wells; MR. Laurent; YF. Williams, Razoxane (ICRF 159) in the treatment of psoriasis., in Br J Dermatol, vol. 102, n. 3, Mar 1980, pp. 307-17, PMID 7370178.
  • JJ. Horton, RS. Wells, Razoxane: a review of 6 years' therapy in psoriasis., in Br J Dermatol, vol. 109, n. 6, Dec 1983, pp. 669-73, PMID 6652043.
  • RB. Mallett, JA. Langtry; JI. Harper; RC. Staughton, Psoriasis, razoxane and a cutaneous B-cell lymphoma., in Br J Dermatol, vol. 116, n. 2, Feb 1987, pp. 243-4, PMID 3493797.
  • EA. Caffrey, MG. Daker; JJ. Horton, Acute myeloid leukaemia after treatment with razoxane., in Br J Dermatol, vol. 113, n. 2, Aug 1985, pp. 131-4, PMID 3861193.
  • S. Lakhani, RN. Davidson; F. Hiwaizi; RA. Marsden, Razoxane and leukaemia., in Lancet, vol. 2, n. 8397, Aug 1984, pp. 288-9, PMID 6146838.
  • WF. Tucker, RE. Church, Beau's lines after razoxane therapy for psoriasis., in Arch Dermatol, vol. 120, n. 9, Sep 1984, p. 1140, PMID 6476851.

oadoi.org